Literature DB >> 9752816

Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia.

M Maclure1, C Dormuth, T Naumann, J McCormack, R Rangno, C Whiteside, J M Wright.   

Abstract

BACKGROUND: The way in which dissemination of evidence changes medical practice needs to be better understood. Controversy about calcium-channel blockers (CCB) in the past 3 years has provided a natural experiment, enabling assessment of the impact of media stories, a national warning letter, a teleconference, small group workshops, and newsletters on first-line prescribing of antihypertensive drugs.
METHODS: We included all physicians (4403) in British Columbia who prescribed a thiazide diuretic, beta-blocker, inhibitor of angiotensin-converting enzyme (ACE), or CCB as the first antihypertensive agent for 36,507 residents aged 66 years and over, with no previous or concurrent sign of underlying cardiovascular disease. We used a database covering all prescriptions to elderly people to measure the change in proportion of newly treated patients who received each class of drug as first-line therapy. We used a matched cohort design for assessment of the teleconference and workshops, a randomised community design for the newsletters, and time-series analysis for the media impacts.
FINDINGS: The proportion of patients who received a CCB as first-line therapy declined gradually from 22% in early 1994 to 15% in late 1996. This proportion was not affected by two waves of adverse news about CCBs in 1995, but fell by 5% for 5 months and by 3% for 1 month after two waves in 1996. The proportion of patients who received either a CCB or an ACE inhibitor as first-line therapy, contrary to guidelines, was still 42% overall in 1996. The workshops and newsletters were followed by shifts from first-line CCB to first-line thiazide prescribing.
INTERPRETATION: Changes in prescribing practices occur gradually with the accumulation of small impacts from educational interventions and lay media attention.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9752816     DOI: 10.1016/S0140-6736(97)11390-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

1.  Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.

Authors:  Alan Cassels; Merrilee A Hughes; Carol Cole; Barbara Mintzes; Joel Lexchin; James P McCormack
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

2.  To what extent do mass media health messages trigger patients' contacts with their GPs?

Authors:  Tina Eriksson; Malcolm Maclure; Jakob Kragstrup
Journal:  Br J Gen Pract       Date:  2005-03       Impact factor: 5.386

3.  Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study.

Authors:  Adrianne Faber; Marcel L Bouvy; Linda Loskamp; Paul B van de Berg; Toine C G Egberts; Lolkje T W de Jong-van den Berg
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 4.  The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future.

Authors:  F A McAlister; N R Campbell; K Zarnke; M Levine; I D Graham
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

5.  Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan.

Authors:  Steven G Morgan
Journal:  Health Serv Res       Date:  2002-10       Impact factor: 3.402

6.  Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing.

Authors:  M E van Eijk; J Avorn; A J Porsius; A de Boer
Journal:  BMJ       Date:  2001-03-17

7.  Methodological approaches to evaluate the impact of FDA drug safety communications.

Authors:  Aaron S Kesselheim; Eric G Campbell; Sebastian Schneeweiss; Paula Rausch; Brian M Lappin; Esther H Zhou; John D Seeger; John S Brownstein; Steven Woloshin; Lisa M Schwartz; Timothy Toomey; Gerald J Dal Pan; Jerry Avorn
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

8.  Bevacizumab for advanced breast cancer: hope, hype, and hundreds of headlines.

Authors:  Michael Fralick; Monali Ray; Christina Fung; Christopher M Booth; Ranjeeta Mallick; Mark J Clemons
Journal:  Oncologist       Date:  2013-09-26

9.  Effect of periodic letters on evidence-based drug therapy on prescribing behaviour: a randomized trial.

Authors:  Colin R Dormuth; Malcolm Maclure; Kenneth Bassett; Ciprian Jauca; Carl Whiteside; James M Wright
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

10.  Mass media release of medical research results: an analysis of antihypertensive drug prescribing in the aftermath of the calcium channel blocker scare of March 1995.

Authors:  Margaret E Brunt; Michael D Murray; Siu L Hui; Joseph Kesterson; Anthony J Perkins; William M Tierney
Journal:  J Gen Intern Med       Date:  2003-02       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.